- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Mutant BRAF in Melanoma
Authors
Keywords
-
Journal
CANCER JOURNAL
Volume 18, Issue 2, Pages 124-131
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2012-03-24
DOI
10.1097/ppo.0b013e31824b436e
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.
- (2017) R. Kefford et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).
- (2017) J. R. Infante et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma
- (2015) William D. Tap et al. NEOPLASIA
- Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
- (2011) Inna V. Fedorenko et al. BIOCHEMICAL PHARMACOLOGY
- Oncogenic BRAF Induces Melanoma Cell Invasion by Downregulating the cGMP-Specific Phosphodiesterase PDE5A
- (2011) Imanol Arozarena et al. CANCER CELL
- Combinatorial Treatments That Overcome PDGFR -Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
- (2011) H. Shi et al. CANCER RESEARCH
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- Protein Kinase D3 Sensitizes RAF Inhibitor RAF265 in Melanoma Cells by Preventing Reactivation of MAPK Signaling
- (2011) J. Chen et al. CANCER RESEARCH
- Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
- (2011) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
- (2011) Patrick A. Oberholzer et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Ipilimumab
- (2011) Vernon K. Sondak et al. NATURE REVIEWS DRUG DISCOVERY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF
- (2011) F Xing et al. ONCOGENE
- Meeting report from the 2011 international melanoma congress, Tampa, Florida
- (2011) Keiran S. M. Smalley et al. Pigment Cell & Melanoma Research
- Embryonic stem-cell-preconditioned microenvironment induces loss of cancer cell properties in human melanoma cells
- (2011) Myoung Ok Kim et al. Pigment Cell & Melanoma Research
- Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma
- (2010) Keith T. Flaherty et al. BIOCHEMICAL PHARMACOLOGY
- Targeted therapies of gastrointestinal stromal tumors (GIST)—The next frontiers
- (2010) Stefan Duensing et al. BIOCHEMICAL PHARMACOLOGY
- Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
- (2010) K H T Paraiso et al. BRITISH JOURNAL OF CANCER
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
- (2010) Y. N. V. Gopal et al. CANCER RESEARCH
- Akt3-Mediated Resistance to Apoptosis in B-RAF-Targeted Melanoma Cells
- (2010) Y. Shao et al. CANCER RESEARCH
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720
- (2010) C. C. Jiang et al. CLINICAL CANCER RESEARCH
- The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
- (2010) U. Banerji et al. CLINICAL CANCER RESEARCH
- Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
- (2010) Jill C Rubinstein et al. Journal of Translational Medicine
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
- (2010) F M Kaplan et al. ONCOGENE
- Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress
- (2010) Keith T. Flaherty Pigment Cell & Melanoma Research
- Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010
- (2010) P. Hersey et al. Pigment Cell & Melanoma Research
- PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas
- (2010) John T. Lee et al. Pigment Cell & Melanoma Research
- PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
- (2010) Ruth Halaban et al. Pigment Cell & Melanoma Research
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- (2010) E. W. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies
- (2010) S. Whittaker et al. Science Translational Medicine
- Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS
- (2010) C C Jiang et al. Cell Death & Disease
- Mitogen-Activated Protein Kinase Inhibition Induces Translocation of Bmf to Promote Apoptosis in Melanoma
- (2009) M. W. VanBrocklin et al. CANCER RESEARCH
- Rnd3 Regulation of the Actin Cytoskeleton Promotes Melanoma Migration and Invasive Outgrowth in Three Dimensions
- (2009) R. M. Klein et al. CANCER RESEARCH
- Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib
- (2009) L. Jilaveanu et al. CLINICAL CANCER RESEARCH
- BRAF Signaling and Targeted Therapies in Melanoma
- (2009) Nathalie Dhomen et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Randomized Phase II Trial Evaluating Two Paclitaxel and Cisplatin–Containing Chemoradiation Regimens As Adjuvant Therapy in Resected Gastric Cancer (RTOG-0114)
- (2009) Gary K. Schwartz et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
- (2009) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Mcl-1 Is Required for Melanoma Cell Resistance to Anoikis
- (2009) K. Boisvert-Adamo et al. MOLECULAR CANCER RESEARCH
- BrafV600E cooperates with Pten loss to induce metastatic melanoma
- (2009) David Dankort et al. NATURE GENETICS
- Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma
- (2009) R. L. Yauch et al. SCIENCE
- Akt3 and Mutant V600EB-Raf Cooperate to Promote Early Melanoma Development
- (2008) M. Cheung et al. CANCER RESEARCH
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel
- (2008) N. K. Haass et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
- (2008) Alex A. Adjei et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
- (2008) K. S.M. Smalley et al. MOLECULAR CANCER THERAPEUTICS
- CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
- (2008) K S M Smalley et al. ONCOGENE
- The role of PTEN signaling perturbations in cancer and in targeted therapy
- (2008) M Keniry et al. ONCOGENE
- Mutant B-RAF mediates resistance to anoikis via Bad and Bim
- (2008) K Boisvert-Adamo et al. ONCOGENE
- Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival
- (2008) Robert A. Cartlidge et al. Pigment Cell & Melanoma Research
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Improving Melanoma Classification by Integrating Genetic and Morphologic Features
- (2008) Amaya Viros et al. PLOS MEDICINE
- B-RAF Regulation of Rnd3 Participates in Actin Cytoskeletal and Focal Adhesion Organization
- (2007) R. Matthew Klein et al. MOLECULAR BIOLOGY OF THE CELL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now